Hongmei Jiang
Shandong Provincial Key Laboratory Of Precision Oncology
Jinan, 250117, China
Jinan, 250117, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Corrigendum to "Bone Marrow stromal cells protect Myeloma cells from ferroptosis through GPX4 deSUMOylation" [Cancer Lett. (2024) 611 217388].
Journal: Cancer letters
Published: March 27, 2025
Bone marrow stromal cells protect myeloma cells from ferroptosis through GPX4 deSUMOylation.
Journal: Cancer letters
Published: August 31, 2024
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.
Journal: Journal for immunotherapy of cancer
Published: February 17, 2023
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression.
Journal: Cancer immunology research
Published: February 01, 2023
Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
Journal: Nature communications
Published: August 18, 2022
Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.
Journal: Oncogene
Published: May 15, 2022
The Role of Palmitoleic Acid in Regulating Hepatic Gluconeogenesis through SIRT3 in Obese Mice.
Journal: Nutrients
Published: February 22, 2022
Chinese natural compound decreases pacemaking of rabbit cardiac sinoatrial cells by targeting second messenger regulation of f-channels.
Journal: eLife
Published: October 29, 2021
NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation.
Journal: Aging cell
Published: October 22, 2021
Melatonin enhances osteoblastogenesis of senescent bone marrow stromal cells through NSD2-mediated chromatin remodelling.
Journal: Clinical and translational medicine
Published: October 20, 2021
Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Journal: Clinical and translational medicine
Published: September 12, 2021
Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation.
Journal: The Journal of clinical investigation
Published: March 12, 2021
Last Updated: 09/26/2026